Statin use and all-cause and cancer mortality: BioBank Japan cohort

被引:24
|
作者
Yokomichi, Hiroshi [1 ]
Nagai, Akiko [2 ]
Hirata, Makoto [3 ]
Tamakoshi, Akiko [4 ]
Kiyohara, Yutaka [5 ]
Kamatani, Yoichiro [6 ]
Muto, Kaori [2 ]
Ninomiya, Toshiharu [7 ]
Matsuda, Koichi [8 ]
Kubo, Michiaki [9 ]
Nakamura, Yusuke [8 ]
Yamagata, Zentaro [1 ]
机构
[1] Univ Yamanashi, Dept Hlth Sci, 1110 Shimokato, Chuo City, Yamanashi 4093898, Japan
[2] Univ Tokyo, Inst Med Sci, Dept Publ Policy, Tokyo, Japan
[3] Univ Tokyo, Inst Med Sci, Lab Genome Technol, Tokyo, Japan
[4] Hokkaido Univ, Dept Publ Hlth, Grad Sch Med, Sapporo, Hokkaido, Japan
[5] Hisayama Res Inst Lifestyle Dis, Fukuoka, Japan
[6] RIKEN, Lab Stat Anal, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan
[7] Kyushu Univ, Grad Sch Med Sci, Dept Epidemiol & Publ Hlth, Fukuoka, Japan
[8] Univ Tokyo, Inst Med Sci, Mol Med Lab, Tokyo, Japan
[9] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan
关键词
Dyslipidaemia; Statins; Anti-cholesterol agents; Colon cancer; Kaplane-Meier estimate; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; RISK; METAANALYSIS; THERAPY; GUIDELINES; EZETIMIBE; SURVIVAL; EFFICACY;
D O I
10.1016/j.je.2016.12.011
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. Kaplan-Meier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64-66 years and mean body mass indices of 24-25 kg/m(2). Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statin monotherapy could potentially reduceany-organ-andcolorectal cancer-relatedmortality. (C) 2017 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological Association.
引用
收藏
页码:S84 / S91
页数:8
相关论文
共 50 条
  • [41] Rheumatoid factor positivity increases all-cause and cancer mortality: a cohort study
    Joong Kyong Ahn
    Jiwon Hwang
    Yoosoo Chang
    Seungho Ryu
    Rheumatology International, 2017, 37 : 1135 - 1143
  • [42] Macronutrient Quality and All-Cause Mortality in the SUN Cohort
    Santiago, Susana
    Zazpe, Itziar
    Fernandez-Lazaro, Cesar, I
    de la O, Victor
    Bes-Rastrollo, Maira
    Angel Martinez-Gonzalez, Miguel
    NUTRIENTS, 2021, 13 (03) : 1 - 17
  • [43] All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
    Petri, Michelle
    Levy, Joseph
    Sbarigia, Urbano
    Goldman, Daniel W.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4081 - 4083
  • [44] GOOD STATIN ADHERENCE REDUCES ALL-CAUSE MORTALITY IN ACUTE HEMORRHAGIC STROKE PATIENTS WITHOUT PRIOR STATIN USE
    Chen, Po-Sheng
    Li, Yi-Heng
    Chang, Ching-Lan
    Yang, Yea-Huei Kao
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 2036 - 2036
  • [45] Early statin therapy reduces all-cause mortality in acute hemorrhagic stroke patients without prior statin use
    Chen, P. -S.
    Li, Y. -H.
    Chang, C. -L.
    Yang, Y. -H. Kao
    EUROPEAN HEART JOURNAL, 2013, 34 : 61 - 61
  • [46] Associations of healthy aging index and all-cause and cause-specific mortality: a prospective cohort study of UK Biobank participants
    Zhuang, Zhenhuang
    Zhao, Yimin
    Huang, Ninghao
    Li, Yueying
    Wang, Wenxiu
    Song, Zimin
    Dong, Xue
    Xiao, Wendi
    Jia, Jinzhu
    Liu, Zhonghua
    Qi, Lu
    Huang, Tao
    GEROSCIENCE, 2024, 46 (01) : 1241 - 1257
  • [47] Associations of healthy aging index and all-cause and cause-specific mortality: a prospective cohort study of UK Biobank participants
    Zhenhuang Zhuang
    Yimin Zhao
    Ninghao Huang
    Yueying Li
    Wenxiu Wang
    Zimin Song
    Xue Dong
    Wendi Xiao
    Jinzhu Jia
    Zhonghua Liu
    Lu Qi
    Tao Huang
    GeroScience, 2024, 46 : 1241 - 1257
  • [48] Dose-response associations of cardiorespiratory fitness with all-cause mortality and incidence and mortality of cancer and cardiovascular and respiratory diseases: the UK Biobank cohort study
    Steell, Lewis
    Ho, Frederick K.
    Sillars, Anne
    Petermann-Rocha, Fanny
    Li, Hiu
    Lyall, Donald M.
    Iliodromiti, Stamatina
    Welsh, Paul
    Anderson, Jana
    MacKay, Daniel F.
    Pell, Jill P.
    Sattar, Naveed
    Gill, Jason M. R.
    Gray, Stuart Robert
    Celis-Morales, Carlos A.
    BRITISH JOURNAL OF SPORTS MEDICINE, 2019, 53 (21) : 1371 - 1378
  • [49] Obesity: Focus on all-cause mortality and cancer
    Teucher, Birgit
    Rohrmann, Sabine
    Kaaks, Rudolf
    MATURITAS, 2010, 65 (02) : 112 - 116
  • [50] Association of all-cause mortality with sugar intake from different sources in the prospective cohort of UK Biobank participants
    Kaiser, Anna
    Schaefer, Sylva M.
    Behrendt, Inken
    Eichner, Gerrit
    Fasshauer, Mathias
    BRITISH JOURNAL OF NUTRITION, 2023, 130 (02) : 294 - 303